Objective: This study examined neurologic abnormalities (as measured by proton magnetic resonance spectroscopy imaging and diffusion tensor imaging), neurocognitive performance, and fatigue among a sample of adults with hepatitis C virus (HCV). We hypothesized that HCV1 individuals would demonstrate structural brain abnormalities and neurocognitive compromise consistent with frontostriatal dysfunction as well as increased fatigue compared to controls.
In the United States, approximately 3.2 million people have hepatitis C virus (HCV), with chronic infection in nearly 75%-85% of cases. 1 HCV is thought to cross the blood-brain barrier primarily by infecting surrounding monocytes and progenitor cells. 2, 3 Consequently, studies have documented neurologic abnormalities and cognitive impairments among HCV1 individuals without advanced liver disease. 4, 5 Studies using proton H magnetic resonance spectroscopy (H-MRS) have demonstrated lower levels of N-acetylaspartate (NAA) in frontal white matter and increases in myo-inosital (mI) and choline/creatine values in the basal ganglia. [6] [7] [8] In a few studies that used diffusion tensor imaging (DTI), patients with HCV demonstrated lower fractional anisotropy (FA) in the inferior fasciculus, the inferior fronto-occipital fasciculus, and the genu of the corpus callosum compared to normal controls. 9, 10 Neurocognitive studies have found that HCV-infected individuals demonstrate increased neurocognitive dysfunction compared to controls. 5, [11] [12] [13] [14] Selective deficits in attention, concentration, and psychomotor speed are most commonly reported across studies, 4, 5, 15, 16 and these deficits are largely independent of such factors as liver fibrosis.
In addition to cognitive dysfunction, approximately 65%-80% of chronically infected patients complain of fatigue that is independent of liver dysfunction. 17 In a study of HCV1 patients, moderate fatigue was associated with poorer cognitive performance and reduced EEG brain activity compared to HCV1 patients with mild fatigue. 8 Fatigue and cognitive dysfunction may share overlapping pathophysiologic mechanisms; however, very few studies have had sufficiently large samples to examine neurocognitive abnormalities and fatigue in tandem. Therefore, the objective of this study was to examine neuroimaging abnormalities (H-MRS and DTI), neurocognitive performance, and fatigue among a sample of HCV1 patients.
METHODS Our initial sample consisted of 87 HCV1 participants who were recruited from several hepatology clinics and infectious disease clinics located throughout the greater Los Angeles catchment area. Controls (n 5 21) were recruited from the community through advertisements and flyers.
Standard protocol approvals, registrations, and patient consents. All procedures received prior approval by the University of California, Los Angeles and VA Greater Los Angeles Healthcare System Institutional Review Board Committees for studies involving human subjects. All HCV1 patients participating in this study met clinical criteria for initiating HCV therapy but had not yet begun treatment. All data reported in the current study were collected at participants' baseline visit. As part of procedures outlined in the parent study, a nested cohort of HCV1 participants underwent neuroimaging (n 5 29). There were no statistically significant differences between HCV1 participants who underwent neuroimaging and those who did not on key demographic variables such as age, sex, ethnicity, past drug abuse, current drug use, Model for End-Stage Liver Disease (MELD) score, and psychiatric functioning (all p values . 0.05). All participants provided informed consent prior to undergoing procedures. Inclusion criteria were as follows: (1) 18 years of age, (2) able to read and write in English, (3) and completed at least 6th grade education. Exclusion criteria were as follows: (1) decompensated cirrhosis/liver failure (detected by blood tests or liver biopsy) with MELD scores .12; (2) current or past psychotic spectrum disorder; (3) significant depression as judged by the study psychiatrists/psychologists (defined as current moderate or severe major depressive disorder) or suicidal ideation (factors that were controlled for initiating interferon treatment); (4) history of learning disability, seizure disorder, closed-head injury with loss of consciousness in excess of 30 minutes, or any other neurologic disease; (5) evidence of any other CNS opportunistic infection or neoplasm; (6) hepatitis B infection; (7) diagnosis of HIV infection as evidenced by HIV antibody testing; (8) recent illicit drug use (confirmed by urine toxicology); and (9) contraindications for MRI (for the nested cohort who underwent neuroimaging). After applying exclusion criteria, our final sample (those eligible for analysis) included 76 HCV1 participants and 20 controls. (See supplementary table e-1 for clinical characteristics of the HCV1 sample.) Ten HCV1 participants were determined to be ineligible due to liver cirrhosis, and 1 control participant tested positive for stimulants at study visit.
Brain MRI was performed using a 3-tesla Trio MRI scanner (Siemens Medical System, Erlangen, Germany). High-resolution MRI included T1-weighted images using a magnetizationprepared rapid acquisition gradient-echo sequence using the following parameters: repetition time (TR)/echo time (TE) 20, 21 ; and motor speed using the Grooved Pegboard test. 25 Raw scores were converted into demographically adjusted t scores, grouped by neurocognitive domain, and averaged to create domain t scores. A global neurocognition score was calculated by averaging t scores from individual neuropsychological tests.
Fatigue was assessed with the Visual Analogue Scale (VAS 26 ). The VAS contains 18 visual analogue lines with bipolar anchors with descriptors relating to energy and fatigue. Participants are asked to place a mark between the anchors. Internal consistency of the VAS in our sample was high (Cronbach a 5 0.86). The total score from the VAS-Fatigue subscale was examined in the current study.
DTI and MRSI postprocessing. DtiStudio was used to create FA and mean diffusivity (MD) maps. We used RoiEditor for preprocessing procedures according to a modified version of the active contour method 27 and DiffeoMap. Images were applied to the JHU-MNI-SS template. Dual-contrast large deformation diffeomorphic metric mapping was used for nonlinear transformations. White matter parcellation map was used to segment the brain into 130 regions based on anatomical labeling, which included both the gray and white matter. Once these regions were extracted, the cortex and the surrounding white matter were segmented using an FA threshold of $0.25. We focused our analyses on regions of the corona radiata, insula, internal capsule, external capsule, striatum, fronto-occiptial fasciculus, cingulum, thalamus, hippocampus, and amygdala based on prior studies. 9, 10, 28, 29 For MRSI, metabolites were quantitated in each voxel using the frequency-domain fitting routine called LC-Model algorithm, which analyzes the in vivo brain spectrum as a linear combination of individual simulated metabolite spectra that constitute the basis set or prior knowledge. 30 We were able to quantify total NAA_NAAG (NAA 1 NAA glutamate), total choline (GPC_Pch), mI, and glutamate/glutamine (Glu_Gln) for regions of frontal white and gray matter, parietal white and gray matter, and basal ganglia (see figure 2 ). The metabolite ratios were normalized with respect to creatine (3.09 ppm). The accuracy of the quantitation was characterized using Cramer-Rao lower bound (CRLB), and metabolite ratios with CRLB ,30% were considered for further analysis.
Preliminary analyses. Demographic characteristics are presented in table. No statistically significant differences were found for potential confounding variables such as age, years of education, ethnicity, and estimated premorbid functioning (as measured by the Wechsler Test of Adult Reading) (all p values . 0.05). Groups also did not differ in current drug use. Between-groups analysis of variance (ANOVA) was used to examine differences between HCV and control groups on our 31 outcome variables of interest: neuroimaging (23 variables), neurocognitive assessment (7 variables), and fatigue (1 variable). Outcome variables were all analyzed on a continuous scale and assumptions for performing ANOVA and Pearson correlations were checked prior to running analyses. Next, DTI and MRSI variables were correlated with neurocognitive performance and fatigue.
We used the false discovery rate (FDR) 31 to correct for multiple comparisons with our outcome measures. FDR is sometimes preferred over family-wise error rate methods (e.g., Bonferroni) because it provides greater statistical power and reduces the chance of making type II errors.
Sensitivity analysis was performed using G*Power version 3.1. Given our available sample size of 96 for the neurocognitive and fatigue data, adjusted a level of 0.01 (for multiple comparisons), and power of 0.80, we had enough power to detect medium effects (f 5 0.31). This is consistent with effect sizes reported in previous investigations that have examined neurocognitive differences between HCV1 patients and controls. 4, 8, 17 For neuroimaging analyses, with a sample of 49, we had enough power to detect medium to large effects. This is also consistent with the effect sizes reported by neuroimaging studies that have compared HCV1 patients to controls. 12, 17 RESULTS DTI. There were statistically significant group differences in FA in the striatum (F 1,48 5 8.49, p , 0.005), with the HCV group demonstrating higher FA levels than controls. While group differences in FA in the thalamus (F 1,48 5 4.6, p 5 0.04) and insula (F 1 figure 1A and table e-2) .
Among the HCV1 group, higher levels of FA in the striatum were correlated with poorer overall neuropsychological performance (r 29 Individuals with chronic HCV infection demonstrated greater MD in the fronto-occiptal fasciculus (F 1 figure 3 and table e-3). For the HCV1 group, greater levels of frontal white matter mI were significantly correlated with poorer cognitive performance in the domains of processing speed (r 29 DISCUSSION The current study examined the effects of chronic HCV infection on microstructural brain abnormalities, cerebral metabolites, fatigue, and neurocognitive performance. Major strengths of the current investigation include the use of DTI and MRSI in combination with measures of neurocognitive functioning and fatigue, and the use of a control group for comparison. As hypothesized based on prior literature, we observed microstructural abnormalities in such areas as the striatum, external capsule, and fronto-occipital fasciculus, which is consistent with previous DTI studies of HCV 9,10 and findings among individuals with HIV infection. 28, 29 We observed greater FA in gray matter regions of the striatum in HCV1 patients compared to healthy volunteers. Higher FA in the striatum has been found among patients with Huntington disease 32 and is thought to be due to degeneration of efferent pathways that increase the coherence of gray matter structures. In a study of patients with chronic subdural hematoma, increased FA was found in the striatum, which reduced following surgical intervention. 33 Therefore, our findings are consistent with other investigations of neuropathology in regions that are affected in HCV.
Increased diffusivity in the fronto-occipital tract and external capsule was also found in the HCV1 group compared to controls. The fronto-occipital tract has been suggested as modulating frontal lobe-related inhibitory control and occipital lobe-related sensory inputs. 34 Alterations of this tract may interfere with integrating sensory information and inhibiting control over impulses and emotion, which is problematic among drug abusers. The external capsule contains a variety of different nerve bundles and pathways connecting the cerebral cortex to subcortical nuclei as well as connecting different parts of the cortex to each other. Therefore, disruption to fibers of the external capsule may result in dysfunction of frontal-subcortical circuitry. HCV1 participants demonstrated lower levels of NAA in bilateral parietal white matter and elevations of mI in bilateral frontal white matter compared to controls, which was associated with poorer performance in the cognitive domains of processing speed and verbal/language fluency. Further, there was a correspondence between our DTI and MRSI measures. Specifically, higher NAA in parietal white matter was significantly correlated with lower diffusivity in the fronto-occipital fasciculus, whereas greater frontal white matter mI was significantly correlated with higher diffusivity in the fronto-occipital fasciculus.
That stated, our MRSI results were generally consistent with previous MRSI studies of HCV1 cohorts, 8, 12, 35 although we did not observe abnormal cerebral metabolite levels in basal ganglia as was expected.
However, in the current study we were careful to exclude participants with medical (e.g., cirrhosis) and psychiatric conditions that potentially could have confounded interpretation of the neuroimaging findings. Through this process we may have excluded HCV1 individuals with more severe neurologic impairments and neuropathologic changes in subcortical structures that are detectable by H-MRS. Although HCV1 patients demonstrated poorer global neurocognitive performance than controls, examination of performance data suggests normal range of performance (i.e., T . 40). Again, because of the use of that has been reported across other studies, 4, 5, 13, 15, 16 and this performance was independent of such factors as liver fibrosis and history of substance abuse. HCV1 participants also reported greater fatigue than controls, which was associated with abnormalities in frontal white matter, whereas poorer cognitive performance was associated with abnormalities in both frontal white matter and subcortical structures. These results suggest that HCV-associated neurologic complications that are specific to changes in frontal-subcortical structures give rise to both reduced cognitive performance and fatigue. The specific cognitive deficits observed in verbal/language fluency and information processing speed are all regulated by frontal-striatal structures. 36 In our sample, verbal fluency demonstrated the greatest degree of performance difference between HCV1 and control groups and the strongest correlation with elevated levels of mI in frontal white matter.
There are limitations to the current study. First, while structural neuroimaging methods are helpful in identifying microstructural pathology that may not be detected on standard MRI, they do not provide a clear understanding about the functions of these neural circuits. Hence, existing disruptions in a neural circuit may make a patient more vulnerable to developing symptoms such as fatigue. Second, although we attempted to control for a number of demographic variables between HCV patients and controls, we recognize that there are a myriad of Figure 4 Neurocognitive performance differences
Neurocognitive performance differences between the hepatitis C group and controls. * 5 Statistically significant at FDR-adjusted p value. psychosocial differences (e.g., stress, past drug use) that may account for the reduced cognitive performance and structural brain differences that were observed in the current study. For instance, we were unable to examine past drug abuse differences between our HCV1 and control groups because information on past drug abuse was not collected from the controls. We recognize that in order to precisely rule out the effects of past drug abuse we would have needed to recruit a sample of past drug abusers who were HCV2. However, considering that 61% of our HCV1 patients reported a lifetime history of cocaine or opiate use, we attempted to address this concern by examining the effects of past drug abuse within this subgroup. While we did not find significant differences in our neuroimaging or neurocognitive data as a function of past drug abuse (all p values . 0.10), we cannot rule out the residual confounding effects of distant substance use on neurologic function. Despite these limitations, the current study represents a significant extension of the extant literature on HCV's effects on neurologic and neurobehavioral functioning by demonstrating how abnormalities in frontal/parietal and subcortical structures have independent and overlapping relationships with cognitive performance and fatigue.
It has long been known that HCV is hepatotoxic; increasingly there is reason to believe that it is neurotoxic as well. While the precise pathophysiologic mechanism remains unclear, findings from the current study as well as others have demonstrated that HCV infection is associated with neurophysiologic and neurobehavioral abnormality. While advances in the pharmacologic treatment of HCV hold incredible promise, there remain millions of HCV-infected adults in the United States and approximately 100 million worldwide. Continued study of the neurologic effects of HCV is needed.
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